VISTIDE

This brand name is authorized in Estonia.

Active ingredients

The drug VISTIDE contains one active pharmaceutical ingredient (API):

1	Cidofovir UNII 768M1V522C - CIDOFOVIR ANHYDROUS
	Cidofovir suppresses HCMV replication by selective inhibition of viral DNA synthesis. Biochemical data support selective inhibition of HSV-1, HSV-2 and HCMV DNA polymerases by cidofovir diphosphate, the active intracellular metabolite of cidofovir.
	Read more about Cidofovir

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VISTIDE Concentrate for solution for infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AB12	Cidofovir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors
Discover more medicines within J05AB12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1204838